Molecular foundations for personalized therapy in prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Prostate cancer, primarily acinar adenocarcinoma, depends on androgen signaling.
• Androgen deprivation therapy is a standard treatment, with ongoing advancements.
• Genetic heterogeneity in prostate cancer significantly impacts treatment strategies.

Purpose of the Study:

• To review recent advancements in prostate cancer treatment.
• To explore the role of molecular genetics in prostate cancer development and targeted therapy.
• To correlate morphologic features with molecular genetics for therapeutic guidance.

Main Methods:

• Review of recent advancements in androgen-deprivation therapy.
• Analysis of genetic landscape, including TMPRSS2-ETS fusions, PTEN inactivation, and PI3K/Akt/mTOR pathway.
• Examination of molecular genetic analysis of aggressive neuroendocrine prostate carcinomas, focusing on Aurora A kinase and N-myc.
• Brief discussion of emerging genetic subtypes (SPINK1, CHD1, SPOP).

Main Results:

• TMPRSS2-ETS fusions are unique to prostate cancer, influencing carcinogenesis and targeted therapy.
• PTEN inactivation activates the PI3K/Akt/mTOR pathway, with prognostic and treatment implications.
• Aggressive neuroendocrine prostate carcinomas show high Aurora A kinase and N-myc overexpression, suggesting targeted inhibitor development.
• Emerging subtypes like SPINK1 overexpression, CHD1 inactivation, and SPOP mutations are identified.

Conclusions:

• Molecular genetics provides deeper insight into prostate cancer heterogeneity than histology alone.
• Targeted therapies are emerging based on specific genetic alterations and molecular subtypes.
• Understanding the interplay between morphology and molecular genetics is crucial for guiding future prostate cancer treatments.